Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

Abstract

The invention relates to opthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an opthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.

What is claimed is:  
     
         1 . A therapeutic composition for topical treatment of ocular hypertension containing a prostaglandin PGA, PGB, PGE or PGF in an amount sufficient to reduce intraocular pressure without causing substantial intraocular irritation and an opthamologically compatible vehicle 
 wherein    the omega chain of the prostaglandin has the formula C 13 -B-C 14 -D-R 2      wherein    C is a carbon atom (the number according to standard prostaglandin nomenclature being indicated by the subscript);    B is a single bond, double bond or triple bond;    D is a subchain comprising 3 carbon atoms and 0-2 heteroatoms selected from the group consisting of O,N and S, having a substitutent on each subchain atom selected from the group consisting of a hydrogen atom, an alkyl group, oxo group and a hydroxyl group; and    R 2  is 17 phenyl which is unsubstituted or has at least one substitutent selected from the group consisting of    C 1 -C 5  alkyl groups,    C 1 -C 4  alkoxy groups,    trifluoromethyl groups,    C 1 -C 3  aliphatic acylamino groups,    nitro groups, and    a phenyl group.    
     
     
         2 . A method of treating glaucoma or ocular hypertension by topical application of a therapeutic composition according to  claim 1.